News Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 01:30:00 2026-01-14 EST			5-day change	1st Jan Change
5,150.00 ^JPY	+2.59%		+4.82%	+6.51%

01-12	Takeda Pharmaceutical Company Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 05:15 PM
01-08	Halozyme Therapeutics, Takeda Collaborate on Vedolizumab Drug Delivery	MT

01-12	Takeda Pharmaceutical Company Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 05:15 PM
01-08	Halozyme Therapeutics, Takeda Collaborate on Vedolizumab Drug Delivery	MT
01-06	Nimbus, Lilly sign deal to develop new oral obesity drug	RE
01-05	Takeda and Protagonist Announce Submission of New Drug Application for Rusfertide for Treatment of Polycythemia Vera	CI
01-05	Takeda Pharmaceutical, Protagonist Submit FDA Application for Rusfertide for Polycythemia Vera Treatment	MT
01-05	Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)	BU
12-30	XOMA Royalty Amends Takeda Deal, Expects Royalties Tied to Broader Asset Portfolio	MT
12-30	XOMA Royalty Corporation Amends Its Collaboration with Takeda Through Strategic Royalty Share Transaction	CI
12-18	Takeda Pharmaceuticals Shares Rise on Positive Psoriasis Treatment Results	DJ
12-18	Takeda's AI-crafted psoriasis pill succeeds in late-stage studies	RE
12-18	Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	MT
12-18	Sector Update: Health Care	MT
12-18	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Amid Incoming Key Inflation Data	MT
12-18	Takeda Pharmaceutical Plans to File Psoriasis Drug Zasocitinib with Regulators in 2026 After Positive Phase 3 Data	MT
12-18	Takeda?s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment	CI
12-18	Takeda Pharmaceutical's Potential Plaque Psoriasis Therapy Meets Endpoints in Phase 3 Studies	MT
12-18	Takeda Pharmaceutical Co Ltd - Zasocitinib landmark Ph3 plaque psoriasis data show promise to deliver clear skin	RE
12-18	Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment	BU
12-16	Takeda Canada: British Columbia reimburses Fruzaqla for treatment of metastatic colorectal cancer	RE
12-16	British Columbia reimburses FRUZAQLATM (fruquintinib capsules) for the treatment of metastatic colorectal cancer (mCRC)	AQ
12-15	Takeda Pharmaceutical Company Limited acquired an unknown minority stake in BaseLaunch.	CI
12-07	Takeda, Protagonist Report One-Year Rusfertide Gains in PV trial	MT
12-06	Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Present Longer-Term Data At ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera	CI
12-06	Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera	BU
12-05	Nikkei Falls Amid Caution Ahead of U.S. Inflation Data, Bond Yields Surge	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Takeda CEO Weber on Drug Pipeline, Geopolitical Risks

January 13, 2025 at 03:31 pm